Lung Cancer Clinical Trial

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Summary

The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer.

The primary study hypotheses state that: 1) the combination of lenvatinib + platinum doublet chemotherapy + pembrolizumab prolongs Progression-free Survival (PFS) as assessed by blinded independent central review (BICR) per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RESIST 1.1) compared to matching placebo + platinum doublet chemotherapy + pembrolizumab, and 2) the combination of lenvatinib + platinum doublet chemotherapy + pembrolizumab prolongs Overall Survival (OS) compared to matching placebo + platinum doublet chemotherapy + pembrolizumab.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of Stage IV (American Joint Committee on Cancer [AJCC], nonsquamous NSCLC.
Confirmation that Epidermal Growth Factor Receptor (EGFR), ALK Receptor Tyrosine Kinase (ALK), or ROS1 Receptor Tyrosine Kinase (ROS1)-directed therapy is not indicated as primary treatment (documentation of absence of tumor-activating EGFR mutations AND absence of ALK and ROS1 gene rearrangements OR presence of a Kirsten Rat Sarcoma (KRAS) gene mutation).
Have measurable disease based on RECIST 1.1. Note: Lesions that appear measurable, but are situated in a previously irradiated area, can be considered measurable (eligible for selection as target lesions) if they have shown documented growth since the completion of radiation.
Provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion (not previously irradiated).
Life expectancy of at least 3 months.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study intervention but before randomization.
Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed.

Male participants must agree for at least 7 days after the last dose of lenvatinib/matching placebo and up to 180 days after the last dose of chemotherapeutic agents to:

Refrain from donating sperm PLUS either:
Be abstinence from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR

Must agree to use contraception unless confirmed to be azoopsermic (vasectomized or secondary to medical cause) as detailed below:

Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.

Note: 7 days after lenvatinib/matching placebo is stopped, if the participant is on pembrolizumab only and is greater than 180 days post chemotherapy, no male contraception measures are needed.

Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

Is not a WOCBP OR
Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days post pembrolizumab and/or 30 days post-lenvatinib/matching placebo, and up to 180 days post last dose of chemotherapeutic agents, whichever occurs last.
Adequate organ function.
Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week prior to randomization. Note: Participants must not have a history of uncontrolled or poorly-controlled hypertension, defined as >150/90 mm Hg for >4 weeks despite standard medical management.

Exclusion Criteria:

Known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, clinically stable, and have not required steroids for at least 14 days prior to the first dose of study intervention.
History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.
Radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel. Additionally, the degree of proximity to major blood vessels should be considered for exclusion because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis after lenvatinib-therapy. (In the chest, major blood vessels include the main pulmonary artery, the left and right pulmonary arteries, the 4 major pulmonary veins, the superior or inferior vena cava, and the aorta).
Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy. Note: The time requirement also does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.
Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.
Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.
Has had allogeneic tissue/solid organ transplant.
Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.
Known history of Hepatitis B. No testing for Hepatitis B or Hepatitis C is required unless mandated by the local health authority.
History of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral drug absorption.
Active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to the first dose of study intervention.
Significant cardiovascular impairment within 12 months prior to the first dose of study intervention, including history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction, cerebrovascular accident (CVA)/stroke, or cardiac arrhythmia associated with hemodynamic instability.
Known history of active tuberculosis.
Active infection requiring systemic therapy.
Has not recovered adequately from any toxicity and/or complication from major surgery prior to the first dose of study intervention.
Previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity to any component of lenvatinib or pembrolizumab, or as applicable, carboplatin, cisplatin, or pemetrexed.
A WOCBP who has a positive urine pregnancy test within 24 hours prior to randomization or treatment allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.
Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC.
Received prior treatment with pembrolizumab or any other anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent, with lenvatinib or any other receptor tyrosine kinase inhibitor (RTKi), or with an agent directed to another stimulatory or co-inhibitory T cell receptor.
Received radiotherapy within 14 days prior to the first dose of study intervention or received lung radiation therapy of >30 Gy within 6 months prior to the first dose of study intervention. Note: Participants must have recovered from all radiation-related toxicities to Grade ≤1, not required corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
Received systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of study intervention.
Received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention. Note: killed vaccines are allowed.
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study intervention.
History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.
Left ventricular ejection fraction (LVEF) below the institutional (or local laboratory) normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

726

Study ID:

NCT03829319

Recruitment Status:

Active, not recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 155 Locations for this study

See Locations Near You

El Camino Hospital Cancer Center ( Site 0529)
Mountain View California, 94040, United States
Yale University ( Site 0519)
New Haven Connecticut, 06520, United States
Holy Cross Hospital ( Site 0512)
Fort Lauderdale Florida, 33308, United States
Mercy Health-Paducah Medical Oncology and Hematology ( Site 0570)
Paducah Kentucky, 42003, United States
Henry Ford Health System ( Site 0563)
Detroit Michigan, 48202, United States
Saint Lukes Cancer Institute ( Site 0541)
Kansas City Missouri, 64111, United States
Broome Oncology, LLC ( Site 0562)
Johnson City New York, 13790, United States
Sanford Health Roger Maris Cancer Center ( Site 0533)
Fargo North Dakota, 58122, United States
Stephenson Cancer Center ( Site 0504)
Oklahoma City Oklahoma, 73104, United States
Good Samaritan Hospital Corvallis ( Site 0521)
Corvallis Oregon, 97330, United States
Thomas Jefferson University Hospital ( Site 0548)
Philadelphia Pennsylvania, 19107, United States
Abington Hospital - Asplundh Cancer Center ( Site 0575)
Willow Grove Pennsylvania, 19090, United States
West Cancer Center - East Campus ( Site 0544)
Germantown Tennessee, 38138, United States
Parkland Health & Hospital System ( Site 0576)
Dallas Texas, 75235, United States
UT Southwestern Medical Center ( Site 0558)
Dallas Texas, 75390, United States
Utah Cancer Specialists ( Site 0523)
Salt Lake City Utah, 84106, United States
West Virginia University ( Site 0526)
Morgantown West Virginia, 26506, United States
Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0367)
Berazategui Buenos Aires, B1884, Argentina
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0371)
Mar del Plata Buenos Aires, B7600, Argentina
CEMIC ( Site 0370)
Buenos Aires Caba, C1431, Argentina
Sanatorio Parque ( Site 0365)
Rosario Santa Fe, S2000, Argentina
Hospital Aleman ( Site 0368)
Buenos Aires , C1118, Argentina
Instituto Medico Especializado Alexander Fleming ( Site 0369)
Buenos Aires , C1426, Argentina
CEMAIC ( Site 0374)
Cordoba , X5008, Argentina
CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica ( Site 0372)
San Juan , J5402, Argentina
Blacktown Hospital Western Sydney Local Health District ( Site 0008)
Blacktown New South Wales, 2148, Australia
Port Macquarie Base Hospital ( Site 0001)
Port Macquarie New South Wales, 2444, Australia
Chris OBrien Lifehouse ( Site 0006)
Sydney New South Wales, 2050, Australia
Westmead Hospital ( Site 0009)
Sydney New South Wales, 2145, Australia
Cairns Hospital ( Site 0002)
Cairns Queensland, 4870, Australia
The Prince Charles Hospital ( Site 0010)
Chermside Queensland, 4032, Australia
Ballarat Health Services ( Site 0003)
Ballarat Victoria, 3350, Australia
Moncton Hospital - Horizon Health Network ( Site 0410)
Moncton New Brunswick, E1C 6, Canada
Juravinski Cancer Centre ( Site 0407)
Hamilton Ontario, L8V 1, Canada
Kingston Health Sciences Centre ( Site 0414)
Kingston Ontario, K7L 2, Canada
Lakeridge Health ( Site 0406)
Oshawa Ontario, L1G 2, Canada
Sault Area Hospital ( Site 0413)
Sault Ste Marie Ontario, P6B 0, Canada
Hopital Cite de la Sante de Laval ( Site 0400)
Laval Quebec, H7M 3, Canada
CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0412)
Montreal Quebec, H3T 1, Canada
CIUSSS de la Mauricie et du Centre du Quebec ( Site 0408)
Trois-Rivieres Quebec, G8Z 3, Canada
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0403)
Quebec , G1R 2, Canada
Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0380)
Temuco Araucania, 48102, Chile
Clinica Universidad Catolica del Maule ( Site 0385)
Talca Maule, 34655, Chile
OrlandiOncologia ( Site 0381)
Santiago Region M. De Santiago, 75007, Chile
Fundacion Arturo Lopez Perez FALP ( Site 0383)
Santiago Region M. De Santiago, 75009, Chile
Pontificia Universidad Catolica de Chile ( Site 0382)
Santiago Region M. De Santiago, 83300, Chile
Bradford Hill Centro de Investigaciones Clinicas ( Site 0387)
Santiago Region M. De Santiago, 84203, Chile
Oncocentro ( Site 0384)
Vina del Mar Valparaiso, 25205, Chile
Centro Oncologico Antofagasta ( Site 0386)
Antofagasta , 12400, Chile
Peking Union Medical College Hospital ( Site 0108)
Beijing Beijing, 10000, China
Cancer Hospital Chinese Academy of Medical Science ( Site 0117)
Beijing Beijing, 10002, China
Beijing Cancer Hospital ( Site 0120)
Beijing Beijing, 10003, China
The Second Hospital Affiliated to AMU ( Site 0119)
Chongqing Chongqing, 40003, China
First Affiliated Hospital of The Third Military Medical University ( Site 0118)
Chongqing Chongqing, 40003, China
Fujian Provincial Cancer Hospital ( Site 0102)
Fuzhou Fujian, 35001, China
Southern Medical University Nanfang Hospital ( Site 0121)
Guangzhou Guangdong, 51051, China
The Third Affiliated Hospital of Harbin Medical University ( Site 0100)
Harbin Heilongjiang, 15008, China
Henan Cancer Hospital ( Site 0112)
Zhengzhou Henan, 45000, China
Wuhan Union Hospital Cancer Center-Cancer Center ( Site 0123)
Wuhan Hubei, 43002, China
Hubei Cancer Hospital ( Site 0122)
Wuhan Hubei, 43007, China
Jilin Cancer Hospital ( Site 0115)
Changchun Jilin, 13010, China
Zhongshan Hospital Fudan University ( Site 0103)
Shanghai Shanghai, 20003, China
Shanghai Pulmonary Hospital ( Site 0101)
Shanghai Shanghai, 20044, China
Tianjin Medical University Cancer Institute & Hospital ( Site 0111)
Tian Jin Tianjin, 30006, China
Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110)
Urumuqi Xinjiang, 83000, China
The First Affiliated Hospital Zhejiang University ( Site 0109)
Hangzhou Zhejiang, 31000, China
Zhejiang Cancer Hospital ( Site 0113)
Hangzhou Zhejiang, 31002, China
The First Affiliated Hospital of Wenzhou Medical University ( Site 0124)
Wen Zhou Zhejiang, 32500, China
Centre Paul Strauss ( Site 0144)
Strasbourg Bas-Rhin, 67065, France
Hopital Nord du Marseille ( Site 0147)
Marseille Bouches-du-Rhone, 13015, France
Hopital Foch ( Site 0145)
Suresnes Hauts-de-Seine, 92151, France
Centre de Cancerologie du Grand Montpellier ( Site 0142)
Montpellier Herault, 34070, France
Hopital Laennec ( Site 0146)
Nantes cedex 1 Loire-Atlantique, 44093, France
Hopital Robert Schuman ( Site 0143)
Vantoux Moselle, 57070, France
Hopital Cardiologique Louis Pradel ( Site 0141)
Bron Rhone-Alpes, 69500, France
L'hopital Nord-Ouest - Centre Hospitalier de Villefranche sur Saone ( Site 0149)
Villefranche sur Saone Rhone, 69655, France
Hopital Cochin ( Site 0140)
Paris , 75014, France
Klinikum Esslingen GmbH ( Site 0164)
Esslingen Baden-Wurttemberg, 73730, Germany
Krankenhaus Nordwest ( Site 0169)
Frankfurt Hessen, 60488, Germany
Pius Hospital Oldenburg ( Site 0170)
Oldenburg Niedersachsen, 26121, Germany
Uniklinik RWTH Aachen ( Site 0160)
Aachen Nordrhein-Westfalen, 52074, Germany
Universitaetsklinikum des Saarlandes ( Site 0165)
Homburg Saarland, 66421, Germany
Krankenhaus Martha Maria Halle-Doelau ( Site 0166)
Halle Sachsen-Anhalt, 06120, Germany
LungenClinic Grosshansdorf GmbH ( Site 0171)
Grosshansdorf Schleswig-Holstein, 22927, Germany
Hamato-Onkologie Hamburg Prof. Laack und Partner ( Site 0161)
Hamburg , 20251, Germany
Soroka Medical Center ( Site 0222)
Beer Sheva , 84101, Israel
Rambam Medical Center ( Site 0223)
Haifa , 31096, Israel
Shaare Zedek Medical Center-Oncology ( Site 0229)
Jerusalem , 90131, Israel
Meir Medical Center ( Site 0221)
Kfar Saba , 44281, Israel
Holy Family Hospital ( Site 0228)
Nazareth , 16411, Israel
Rabin Medical Center ( Site 0224)
Petah Tikva , 49414, Israel
Sheba Medical Center ( Site 0220)
Ramat Gan , 52620, Israel
Sourasky Medical Center ( Site 0225)
Tel Aviv , 64239, Israel
Shamir Medical Center-Assaf Harofeh ( Site 0227)
Zerifin , 70300, Israel
National Hospital Organization Nagoya Medical Center ( Site 0017)
Nagoya Aichi, 460-0, Japan
Fujita Health University Hospital ( Site 0016)
Toyoake Aichi, 470-1, Japan
National Cancer Center Hospital East ( Site 0024)
Kashiwa Chiba, 277-8, Japan
Kanazawa University Hospital ( Site 0018)
Kanazawa Ishikawa, 920-8, Japan
Osaka Habikino Medical Center ( Site 0020)
Habikino Osaka, 583-8, Japan
Kansai Medical University Hospital ( Site 0022)
Hirakata Osaka, 573-1, Japan
Niigata Cancer Center Hospital ( Site 0019)
Niigata , 951-8, Japan
National Cancer Center Hospital ( Site 0026)
Tokyo , 104-0, Japan
Tokyo Metropolitan Komagome Hospital ( Site 0015)
Tokyo , 113-8, Japan
The Cancer Institute Hospital of JFCR ( Site 0021)
Tokyo , 135-8, Japan
Wakayama Medical University Hospital ( Site 0025)
Wakayama , 641-8, Japan
Chungbuk National University Hospital ( Site 0062)
Cheongju si Chungbuk, 28644, Korea, Republic of
National Cancer Center ( Site 0061)
Goyang-si Kyonggi-do, 10408, Korea, Republic of
The Catholic University of Korea St. Vincent s Hospital ( Site 0064)
Gyeonggi-do Kyonggi-do, 16247, Korea, Republic of
Severance Hospital Yonsei University Health System ( Site 0063)
Seoul , 03722, Korea, Republic of
Tauranga Hospital ( Site 0004)
Tauranga Bay Of Plenty, 3112, New Zealand
Auckland City Hospital ( Site 0011)
Auckland , 1023, New Zealand
Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 0601)
Bydgoszcz Kujawsko-pomorskie, 85-79, Poland
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii ( Site 0613)
Lodz Lodzkie, 93-51, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0603)
Warszawa Mazowieckie, 02-78, Poland
Pleszewskie Centrum Medyczne w Pleszewie Sp. z o.o. ( Site 0615)
Pleszew Wielkopolskie, 63-30, Poland
MED-POLONIA Sp. z o.o. ( Site 0609)
Poznan Wielkopolskie, 60-69, Poland
Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0602)
Koszalin Zachodniopomorskie, 75-58, Poland
Leningrad Regional Oncology Center ( Site 0271)
Saint Petersburg Leningradskaya Oblast, 19775, Russian Federation
Moscow Regional Oncological Dispensary ( Site 0274)
Balashikha Moskovskaya Oblast, 14390, Russian Federation
City Clinical Hospital 1 na. NI. Pirogov ( Site 0270)
Moscow Moskva, 11904, Russian Federation
Central Clinical Hospital with outpatient Clinic ( Site 0262)
Moscow Moskva, 12135, Russian Federation
National Medical Research Radiology Centre ( Site 0260)
Moscow Moskva, 12528, Russian Federation
FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0264)
Moscow Moskva, 12536, Russian Federation
Nizhniy Novgorod Region Oncology Dispensary ( Site 0272)
Nizhniy Novgorod Nizhegorodskaya Oblast, 60308, Russian Federation
Omsk Clinical Oncology Dispensary ( Site 0267)
Omsk Omskaya Oblast, 64401, Russian Federation
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0269)
Saint Petersburg Sankt-Peterburg, 19775, Russian Federation
First Pavlov State Medical University of Saint Petersburg-Department of Oncology ( Site 0273)
Saint-Petersburg Sankt-Peterburg, 19702, Russian Federation
SAHI Republican Clinical Oncological Dispensary of the MoH of RT ( Site 0261)
Kazan Tatarstan, Respublika, 42002, Russian Federation
ICO L Hospitalet ( Site 0234)
Hospitalet de Llobregat Barcelona, 08907, Spain
Complejo Hospitalario Universitario A Coruna ( Site 0239)
A Coruna La Coruna, 15006, Spain
Hospital Universitario Insular de Gran Canaria ( Site 0244)
Las Palmas de Gran Canaria Las Palmas, 35001, Spain
Hospital General Universitario de Valencia ( Site 0231)
Valencia Valenciana, Comunitat, 46014, Spain
Hospital Universitario La Fe ( Site 0233)
Valencia Valenciana, Comunitat, 46026, Spain
Hospital General Universitario de Alicante ( Site 0240)
Alicante , 03010, Spain
Hospital Santa Creu i Sant Pau ( Site 0241)
Barcelona , 08025, Spain
Hospital General Universitario Gregorio Maranon ( Site 0237)
Madrid , 28009, Spain
Hospital Clinico San Carlos ( Site 0235)
Madrid , 28040, Spain
Hospital Universitario La Paz ( Site 0236)
Madrid , 28046, Spain
Complejo Hospitalario de Malaga ( Site 0238)
Malaga , 29010, Spain
Hospital Universitario Miguel Servet ( Site 0242)
Zaragoza , 50009, Spain
Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 0314)
Adana , 01330, Turkey
Hacettepe Universitesi Tıp Fakultesi ( Site 0316)
Ankara , 06100, Turkey
Ankara Universitesi Tip Fakultesi. ( Site 0317)
Ankara , 06620, Turkey
Ankara Sehir Hastanesi ( Site 0323)
Ankara , 06800, Turkey
Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0312)
Istanbul , 34098, Turkey
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0310)
Istanbul , 34722, Turkey
Ege Universitesi Tip Fakultesi ( Site 0313)
Izmir , 35100, Turkey
Inonu Universitesi Medical Fakultesi ( Site 0318)
Malatya , 44280, Turkey
Cambridge University Hospitals NHS Trust ( Site 0293)
Cambridge Cambridgeshire, CB2 0, United Kingdom
North Middlesex University Hospital NHS Trust ( Site 0291)
London London, City Of, N18 1, United Kingdom
Guys and St Thomas NHS Foundation Trust ( Site 0280)
London London, City Of, SE1 9, United Kingdom
St Georges University Hospitals NHS Foundation Trust. ( Site 0292)
London London, City Of, SW17 , United Kingdom
Aberdeen Royal Infirmary ( Site 0288)
Aberdeen Scotland, AB25 , United Kingdom
Leeds Teaching Hospital NHS Trust. St. James University Hospital ( Site 0276)
Leeds , LS9 7, United Kingdom
Leicester Royal Infirmary ( Site 0284)
Leicester , LE1 5, United Kingdom
Christie NHS Foundation Trust ( Site 0275)
Manchester , M20 4, United Kingdom
Nottingham City Hospital Campus ( Site 0287)
Nottingham , NG5 1, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0286)
Wirral , CH63 , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

726

Study ID:

NCT03829319

Recruitment Status:

Active, not recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.